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General methods.
The purified TEM-1 β-lactamase was customarily prepared by the Biologics Process Development, Inc. (San Diego, California). Penicillinase from Bacillus cereus was purchased from Sigma-Aldrich (catalogue No. P0389). Recombinant BlaC was expressed in E. coli as previously described (1) . All chemicals were purchased from commercial sources. K. pneumonia with SHV-18, E. cloacae with AmpC, K. pneumoniae with KPC, and E. coli with NDM-1 lysates were kindly provided by Dr. Niaz Banaei from the Stanford Medical Center Microbiology Lab. Fluorescence spectra were obtained on a Fluoromax-3 spectrafluorometer (Jobin Yvon). Kinetic experiments were performed in a M1000 microplate reader (TECAN, research triangle park, NC). Analytical TLC was performed with 0.25 mm silica gel 60F plates with fluorescent indicator (254 nm). The 1 H and 13 C NMR spectra were taken on
Varian 400 MHz magnetic resonance spectrometer. Data for 1 H NMR spectra are reported as follows: chemical shifts are reported as δ in units of parts per million (ppm) relative to chloroform-d (δ 7.26, s); multiplicities are reported as follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), m (multiplet), or br (broadened); coupling constants are reported as a J value in Hertz (Hz); the number of protons (n) for a given resonance is indicated nH, and based on the spectral integration values. HPLC was performed on a Dionex HPLC System (Dionex Corporation) equipped with a GP50 gradient pump and an inline diode array UV-Vis detector. A reversed-phase C18 (Phenomenax, 5 µm, 10 x 250 mm or Dionex, 5 µm, 4.6 x 250 mm) column was used with a MeCN (B) / H 2 O (A) gradient mobile phase containing 0.1% trifluoroacetic acid at a flow of 1 or 3 mL/min for the analysis.
pooled TB negative human sputum. Sputa were diluted 1:1 in in 200 mM MES buffer pH 6 plus 2% DTT, which constitutes transport stabilization solution (TSS), and incubated 0.3 generations (~40 min for BCG, 5 min for M. smegmatis, E. coli, PA01 and MRSA) at room temperature. Reporter enzyme fluorescence solution (REFS; CDG-3 in 200 mM MES), was added and samples read immediately and after 40 min at room temperature in a 96-well plate using a Mithras LB940 plate reader at 490 nm (ex) and 535 nm (em). For clinical samples testing using CDG-3, the obtained samples were mixed thoroughly with TSS (1:1) to achieve homogenization. The homogenized sample was incubated for one hour at room temperature before addition of REFS. The samples were read immediately using a Mithras LB940 plate reader at 490 (ex) and 535 (em), using a 100-point scan protocol. Each sample set was processed with two negative controls, a TSS control comprised of only TSS (no sputum) and the synthetic sputum control made as described previously (2) .
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S3 a Kinetic data were measured in MES buffer (100 mM, pH = 6.6, with 0.1% surfactant (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate)) at room temperature (22°C 
Enzymatic kinetics and stability tests.
Enzymatic kinetics and stability tests of new analogues were determined as previously reported (3). 
Benzhydryl(7R,6R)-7-(2-phenylacetamido)-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-2-methylene-1-oxide-3-cephem-4-carboxylate (11).
Compound 11 was prepared according to a method modified from literature(3). To a solution of 10 (802 mg, 1.19 mmol)(4) and formaldehyde (37% aqueous solution, 1 mL, 12.3 mmol) in DMF (7.5 mL) and dioxane (7.5 mL) was added dimethylamine hydrochloride (194 mg, 2.4 mmol) and the reaction mixture was heated to 55 ºC for 6 h. After starting material disappeared (monitored by TLC), solvent and excess reagent were removed by Rota-Vap. Purification by flash chromatography on silica gel column afforded the titled compound 11 (661mg, 84% Scheme S1. Synthesis of 2R-CDC-1 and 2S-CDC-1
6R, 2R)-7-(2-phenylacetamido)-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-2-((ethylthio)methyl)-3-cephem-4-carboxylic acid (2R-CDC-1).
To a mixture of 11 (68.9 mg, 0.1 mmol) and NaHCO 3 (4 mg, 0.05 mmol) in DMF (0.5 mL) was added ethanethiol (10 µL, 0.14 mmol) and the reaction was stirred at room temperature for 0.5 h. After starting material 11 disappeared, compound 12 as crude product was obtained after flash chromatography on a short silica gel column. Under Ar, trifluoroacetic anhydride (71 µL, 0.5 mmol) was added slowly to a mixture of sodium iodide (150 mg, 1 mmol) and compound 12 in acetone (anhydrous, 7 mL) at -40 ºC, the reaction mixture was then stirred at -20 ºC for 1 h. After the disappearance of 12, reaction was cooled down to -78 ºC and ethyl acetate was added, followed by sodium bicarbonate saturated aqueous solution. The reaction temperature was then allowed to room temperature. Organic layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over MgSO 4 . Crude compound 13 was then obtained after solvent was removed (the 1 H NMR spectrum of the crude product to be 77.8: 22.2), which was then subjected to a mixture CH 2 Cl 2 /TFA/TIPS (1/0.9/0.05 mL) at room temperature for 5 minutes. Pure 2R-CDC-1 (6 mg, 11% for 3 steps) and 2S-CDC-1 (25 mg, 44% for 3 steps) were obtained after HPLC purification on a C18 column. 2R-CDC 
Benzhydryl(7R,6R)-7-(2-phenylacetamido)-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-2-methylene-3-cephem-4-carboxylate (14)
Under Ar, trifluoroacetic anhydride (350 µL, 2.48 mmol) was added slowly to a mixture of sodium iodide (735 mg, 14.7 mmol) and compound11 in acetone (anhydrous, 20 mL) at -40 ºC, the reaction mixture was then stirred at -20 ºC for 1 h. The reaction was cooled down to -78 ºC and ethyl acetate was added, followed by sodium bicarbonate saturated aqueous solution. The reaction temperature was then raised to room temperature. Organic layer was separated and the aqueous layer was S10 extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over MgSO 4 
Benzhydryl(7R,6R)-7-(2-phenylacetamido)-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-2-c yclopropyl-3-cephem-4-carboxylate (15)(5)
. Caution! Diazomethane is carcinogenic and potentially explosive! Erlenmeyer flasks (no ground joints) were used in reaction. To a S11 solution of 14 (314 mg, 0.47 mmol) in CH 2 Cl 2 (20 mL) at 0 ºC was added diazomethane(6) (4.7 mmol) in ethyl ether (20 mL) and the reaction was kept at 0 ºC for 3 h. After the reaction completed, acetic acid was added slowly at 0 ºC to quench the excess diazomethane (until the reaction solution turned from yellow to colorless). -Cp)(4, 7) . Under Ar, a solution of lithium methoxide (19.4 mg, 0.5 mmol) in methanol (anhydrous, 0.6 mL) was added dropwise to a solution of 15 (137 mg, 0.2 mmol) in anhydrous THF (3 mL) at -78 ºC and the reaction was stirred for 5 min. Tert-butyl hypochlorite (36 µL, 0.32 mmol) was then added dropwise and the mixture was stirred at the same temperature for half an hour. Anhydrous THF (5 mL) was added to dilute and the resulting solution was poured in one port to an aqueous solution containing ammonium chloride and sodium bisulfite, extracted with ethyl acetate (15 mL x 3) and dried over MgSO 4 . Compound 16 was obtained as crude product after solvent was removed, which was then treated with a mixture CH 2 Cl 2 /TFA/TIPS (1/0.9/0.05 mL) at room temperature for 5 minutes. The titled compound CDC-OMe-Cp (45 mg, 39% for 2 steps) was obtained after HPLC purification. -1-oxide-3-cephem-4-carboxylate (4) . To a solution of 3(4) (500 mg, 0.785 mmol) and formaldehyde (37% aqueous solution, 0.64 mL, 7.9 mmol) in DMF (6 mL) and dioxane (6 mL) was added dimethylamine hydrochloride (128 mg, 1.57 mmol) and the reaction mixture was heated to 55 ºC for 6 h. Solvents and excess reagent were removed by Rota-Vap. Purification by flash chromatography on silica gel column afforded the titled compound 4 (418 mg, 82%). 
(7S, 6R)-7-(2-phenylacetamido)-7-methoxy-3-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-

S12
2-cyclopropyl-3-cephem-4-carboxylic acid (CDC-OMe
Benzhydryl(7R,6R)-7-(2-phenylacetamido)-3-((4-(chloromethyl)phenoxy)methyl)-2-cycl opropyl-3-cephem-4-carboxylate (7)
. Under Ar, trifluoroacetic anhydride (304 µL, 2.2 mmol) was added slowly to a mixture of sodium iodide (645 mg, 4.3 mmol) and 2 (275 mg, 0.43 mmol) in acetone (anhydrous, 10 mL) at -40 ºC, the reaction mixture was then stirred at -20 ºC for 1 h. Reaction mixture was cooled down to -78 ºC and ethyl acetate was added, followed by sodium bicarbonate saturated aqueous solution. The reaction temperature was then allowed to rise to room temperature. Organic layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over MgSO 4 and the solvent was removed to afford 5. To a solution of 5 in CH 2 Cl 2 (4 mL) at 0 ºC was added fresh prepared diazomethane 5 (Caution! Diazomethane is carcinogenic and potentially explosive! 4.9 mmol) in ethyl ether (10 mL) and the reaction was kept at 0 ºC for 4 h. After the reaction completed, acetic acid (0.5 mL) was added slowly at 0 ºC to quench the excess diazomethane (until the reaction solution turned from yellow to colorless). The resulting mixture was washed with water and NaHCO 3 aqueous solution subsequently, and S14 dried over MgSO 4 . After filtration and Rota-Vap, the residue was dissolved in ethyl acetate (15 mL) and heated to 50 ºC for 40 min. After solvent removal, the residue was purified by flash chromatography on silica gel column by using hexane/ethyl acetate (5/1-3/1) to afford the crude compound 6. To a solution of 6 obtained above, 2,6-lutidine (93 µL, 0.8 mmol) in DMF (anhydrous, 1.5 mL) at 0 ºC, was added slowly methanesulfonyl chloride (42 µL, 0.54 mmol). The reaction was stirred at 0 ºC for 0.5 h and room temperature for 1 h. Lithium chloride (230 mg, 5.4 mmol) was then added and stirred at room temperature for another 2 h. Ethyl acetate and water were added. After separation, the aqueous layer was further extracted with ethyl acetate twice. The combined organic layer was washed with water and brine, and dried over MgSO 4. After solvents removal, the residue was then purified by flash chromatography on silica gel column by using hexane/ethyl acetate (3/1) as eluting solvents to afford the titled compound 7 (136 mg, 48% for 3 steps from 4). 1 
